Associations - HER-2 exon 20 insertion

HER-2 exon 20 insertion HER-2 exon 20 insertion	Solid Tumor Solid Tumor	HER-2 exon 20 insertion HER-2 exon 20 insertion	Solid Tumor Solid Tumor	BDTX-189 Sensitive: B - Late Trials	BDTX-189 Sensitive: B - Late Trials
HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	pyrotinib Sensitive: C2 – Inclusion Criteria	pyrotinib Sensitive: C2 – Inclusion Criteria
HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	HM 78136B Sensitive: C2 – Inclusion Criteria	HM 78136B Sensitive: C2 – Inclusion Criteria
HER-2 exon 20 insertion HER-2 exon 20 insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20 insertion HER-2 exon 20 insertion	Lung Adenocarcinoma LUAD	ado-trastuzumab emtansine Sensitive: C3 – Early Trials	ado-trastuzumab emtansine Sensitive: C3 – Early Trials
HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: C3 – Early Trials	dacomitinib Sensitive: C3 – Early Trials
HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	pyrotinib + rivoceranib Sensitive: C3 – Early Trials	pyrotinib + rivoceranib Sensitive: C3 – Early Trials
HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	KN046 Sensitive: C3 – Early Trials	KN046 Sensitive: C3 – Early Trials
HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	ado-trastuzumab emtansine Sensitive: C3 – Early Trials	ado-trastuzumab emtansine Sensitive: C3 – Early Trials
HER-2 exon 20 insertion HER-2 exon 20 insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20 insertion HER-2 exon 20 insertion	Lung Adenocarcinoma LUAD	afatinib Sensitive: C4 – Case Studies	afatinib Sensitive: C4 – Case Studies
HER-2 exon 20 insertion HER-2 exon 20 insertion	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HER-2 exon 20 insertion HER-2 exon 20 insertion	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine + neratinib Sensitive: D – Preclinical	ado-trastuzumab emtansine + neratinib Sensitive: D – Preclinical
HER-2 exon 20 insertion HER-2 exon 20 insertion	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HER-2 exon 20 insertion HER-2 exon 20 insertion	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical	neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
HER-2 exon 20 insertion HER-2 exon 20 insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20 insertion HER-2 exon 20 insertion	Lung Adenocarcinoma LUAD	HM 78136B Sensitive: D – Preclinical	HM 78136B Sensitive: D – Preclinical